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Abstract
Extracellular matrix (ECM) degradation after myocardial infarction (MI)
leaves the myocardium structurally weakened and, as a result, susceptible to
early infarct zone dyskinesia and left ventricular (LV) remodeling. While various cellular and biomaterial preparations have been transplanted into the
infarct zone in hopes of improving post-MI LV remodeling, an allogeneic cardiac muscle-derived ECM extract has yet to be developed and tested in the
setting of reperfused MI. We sought to determine the effects of injecting a
novel cardiac muscle-derived ECM into the infarct zone on early dyskinesia
and LV remodeling in a mouse model of MI. Cardiac muscle ECM was
extracted from frozen mouse heart tissue by a protocol that enriches for basement membrane constituents. The extract was injected into the infarct zone
immediately after ischemia/reperfusion injury (n = 6). Echocardiography was
performed at baseline and at days 2, 7, 14, and 28 post-MI to assess 3D LV
volumes and cardiac function, as compared to infarcted controls (n = 9).
Early infarct zone dyskinesia was measured on day 2 post-MI using a novel
metric, the dyskinesia index. End-systolic volume was significantly reduced in
the ECM-treated group compared to controls by day 14. Ejection fraction and
stroke volume were also significantly improved in the ECM-treated group.
ECM-treated hearts showed a significant (P < 0.005) reduction in dyskinetic
motion on day 2. Thus, using high-frequency ultrasound, it was shown that
treatment with a cardiac-derived ECM preparation reduced early infarct zone
dyskinesia and post-MI LV remodeling in a mouse model of reperfused MI.

doi: 10.14814/phy2.12351
Physiol Rep, 3(3), 2015, e12351,
doi: 10.14814/phy2.12351

Introduction
In its acute stage, myocardial infarction (MI) results in
immediate death to cardiomyocytes and contractile dysfunction. Immune cells infiltrate the area of infarction to
phagocytize necrotic cells and apoptotic cell debris, and
release enzymes that degrade the cardiac extracellular
matrix (ECM) (Dai et al. 2005; French and Kramer 2007;

Jourdan-Lesaux et al. 2010). This causes the infarct zone
to become thinned, structurally weak, and susceptible to
paradoxical bulging under the pressure of systole (early
dyskinesia) (Dai et al. 2005; French and Kramer 2007;
Gersh et al. 2009) prior to scar formation. Early dyskinesia not only robs the heart of systolic function, but is also
correlated with maladaptive long-term changes in heart
morphology and function, and thus may contribute
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importantly to left ventricular (LV) remodeling and eventual heart failure (French and Kramer 2007).
Although a number of clinical studies have shown that
the transplantation of progenitor or stem cells into the
LV after MI can marginally improve cardiac function, the
data from most such studies fail to show clinically significant levels of differentiation (much less survival) of the
transplanted cells (Gersh et al. 2009). These data suggest
that the major benefits of cell transplantation therapy
may not result from replacing lost cardiomyocytes, but
rather from the injected cells serving to reinforce the
infarcted LV walls via a scaffolding effect (Dai et al. 2005)
or by producing cytokines and growth factors that stimulate regeneration (Gnecchi et al. 2005).
These current hypotheses surrounding stem cell transplantation therapy support a strategy involving acellular
therapy. ECM components are an attractive material for
acellular therapy because they serve a structural function
and promote cellular adhesion, proliferation, and differentiation (Akhyari et al. 2008). Transplanted ECM
derived from porcine urinary bladders has been found to
become populated with myocytes and improve regional
contractile function in several animal models (Kelly et al.
2009; Singelyn and Christman 2010). ECM composition
is complex, however, and highly variable among species
and cell types and the composition of the extract will
almost certainly determine its properties. Recently, a hydrogel derived from porcine cardiac ECM was found to
preserve cardiac function in a rat MI model (Singelyn
et al. 2012).
Matrigel (BD Biosciences, San Jose, CA), a reconstituted
basement membrane-rich extract, has been widely used as a
cell culture substrate for over 30 years (Kleinman et al.
1986). While Matrigel has been implanted to treat postinfarct myocardium, it is derived from a mouse sarcoma and
is thus comprised of noncardiac matrix components and is
potentially immunogenic outside the mouse, limiting its
clinical potential (Singelyn and Christman 2010). The biochemical protocol used in Matrigel production can be
adapted, however, to other basement membrane-rich tissues such as skeletal muscle (Abberton et al. 2008).
This study sought to determine whether a novel cardiac
muscle-derived ECM extract (“cMatrix”) could improve
cardiac function after reperfused MI. In order to test the
therapeutic potential of cMatrix, high-frequency 3D echocardiography was used to serially assess cardiac function
over 28 days in a mouse model of reperfused MI. Cardiac
magnetic resonance (CMR) was performed in a subset of
mice on day 2 post-MI to determine infarct size, and on
day 28 post-MI to confirm volumetric results. A new metric, here termed the “dyskinesia index” (DI), was developed
to measure early infarct zone dyskinesia, based on wallmotion data acquired from ultrasound image processing.
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Materials and Methods
Experimental design
The experimental design of this study is summarized in
Figure 1. 3D echocardiography was performed at baseline
and on days 2, 7, 14, and 28 post-MI and involved the
capture of a full sweep of short-axis (SA) cines from the
apex to the base of the LV at 1.0 mm intervals. This
imaging was achieved using a custom-built hardware/software system that controlled the ultrasound transducer
and triggered the scanner to acquire and store data,
allowing for the full SA stack to be captured in less than
1 min. A novel metric based on the ratio of signed to
unsigned endocardial displacement, here termed the “dyskinesia index” (DI), was employed to quantify early
infarct zone dyskinetic motion on post-MI D2. MRI was
performed in a subset of mice on D2 post-MI to determine infarct size, and on D28 post-MI to confirm volumetric results.

Tissue harvesting for cMatrix
This study was conducted under protocols approved by
the University of Virginia Animal Care and Use Committee. Adult male C57Bl/6 mice purchased from The
Jackson Laboratory (Bar Harbor, ME) were killed with an
overdose of anesthetic and death was confirmed by cervical dislocation. Hearts were then immediately excised,
rinsed in chilled phosphate-buffered saline (PBS), and
atria were removed. The tissue was then snap-frozen in
liquid nitrogen and stored at 80°C.

cMatrix production
All procedures were performed at 4°C. Frozen mouse tissue was thawed from 70°C in buffered 3.4 M NaCl with
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Figure 1. Experimental Design. Fifteen mice received a 1-h
coronary occlusion followed by reperfusion on day 0 (MI). Nine of
these mice were left untreated, while six received cMatrix injection
at reperfusion. All mice were studied using 3D echocardiography,
both at baseline and at 2, 7, 14 and 28 days post-MI. DI analysis
was performed using data collected on day 2 post-MI. MRI scans
were performed in a subset of mice on day 2 post-MI to determine
infarct size, and on day 28 post-MI to confirm volumetric results.

ª 2015 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.

D. M. O’Connor et al.

added protease inhibitors [5 mM ETDA, 2 mM NEM
(Sigma-Aldrich, St. Louis, MO)], in a volume six times
the weight of the sample. The sample was minced into
approximately 1 mm3 pieces using a scalpel and homogenized. The homogenized mixture was then spun at
10,000 9 g for 30 min. The pellet was washed with a
2 M buffered urea solution at a volume equal to the original weight of the tissue. The sample was then stirred
overnight. Next, the sample was centrifuged at
18,000 9 g for 30 min and the supernatant was decanted
and stored at 4°C. Two additional extractions were performed by resuspending and homogenizing the pellet in
urea buffer of one-half the volume of the original tissue
weight, and repeating the centrifugation. Aliquots from
each sample were evaluated for total protein and collagen
content to assess quality. The combined supernatants
were then dialyzed against 0.5% chloroform in tris-buffered saline (TBS) overnight to sterilize the extract. The
extract was further dialyzed twice against TBS to remove
the urea and chloroform, and once against PBS to
enhance physiological compatibility. The final extract was
aliquoted and stored at 20°C.

Protein concentration measurements
Total protein concentration was measured using an assay
kit based on the Lowry method (Bio-Rad, Hercules, CA).
Collagen content was determined using the Sircol soluble
collagen assay kit (Biocolor; Accurate Chemical & Scientific Corporation, Westbury, NY).

Biomaterial Protects Against LV Remodeling

Vevo 2100 high-resolution ultrasound scanner (VisualSonics Inc., Toronto, ON, Canada). Anesthesia, body
temperature, and EKG monitoring were performed as
described previously (Li et al. 2011).
Six to seven serial parasternal left ventricular (LV)
short-axis (SA) views were captured from the apex to the
base of the LV in 1.0 mm intervals using a custom-built
hardware/software system that controlled the motor stage
holding the transducer and triggered the scanner to
acquire and store image data. This system allowed for the
full SA stack to be captured in less than one minute.
Sequences averaged 30–40 frames per cardiac cycle. The
total ultrasound imaging session duration was under
30 min per mouse.
Left ventricular short-axis cross-sectional areas were
calculated by manually delineating endocardial contours
at end-diastole (ED) and end-systole (ES) at 1 mm intervals from apex to base. ED and ES were determined on a
per slice basis. The LV end-systolic volumes (LVESV) and
LV end-diastolic volumes (LVEDV) were then computed,
and ejection fraction (EF) and stroke volume (SV) were
derived from these values.
The extent of wall thinning was calculated from endocardial and epicardial traces of long-axis images at enddiastole. Significant wall thinning was defined as a left
ventricular wall thickness of 0.5 mm or thinner, relative
to the normal end-diastolic wall thickness of 1 mm. The
extent was defined as the percentage of the LV wall in
which significant wall thinning occurred.

Echocardiography data analysis
Mouse model of reperfused MI
Male C57Bl/6 mice were purchased from Jackson Laboratories (Bar Harbor). The mice were between 10–12 weeks
old and weighed 24–29 g at the time of surgery. A standard myocardial ischemia/reperfusion protocol was
employed, as described previously (Li et al. 2011). Briefly,
the hearts of anesthetized mice were exposed via left thoracotomy, and occlusion was induced by passing a suture
around the left anterior descending coronary artery and
tightening it over a piece of polyethylene-60 tubing for
60 min. For the group of mice receiving cMatrix, 15 lL
were injected directly into the anterolateral sector of apical myocardium using a 31-gauge insulin syringe.

Echocardiography
All mice were studied by echocardiography at baseline
and 2, 7, 14, and 28 days after myocardial infarction
(MI). Prior to scanning, fur was shaved from the chest
followed by depilation with Nair cream. Ultrasound Bmode cardiac image sequences were acquired using a

A novel metric, here termed the “dyskinesia index” (DI)
was employed to quantify early infarct zone dyskinetic
motion, based on contraction index, as described by Li
et al. (2011). DI is a measure based on the efficiency (eff)
of endocardial displacement, which is defined as the ratio
of the sum of signed radial displacements to the sum of
unsigned radial displacements for each time point in the
cardiac cycle:
eff ðtÞ ¼

Ri dði; tÞ
Ri jdði; tÞj

(1)

In this equation, “d” is the mean radial displacement
of each segment “i”, at time point “t”. DI is defined as
the average value of eff(t) over the course of the cardiac
cycle (from t0 to tN):
DI ¼

1
tN  t0

ZtN
eff ðtÞdt

(2)

t0

Thus, DI represents the average ratio of the sum of the
signed radial displacements to the sum of the unsigned

ª 2015 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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radial displacements, over the cardiac cycle. DI yields
possible values ranging from 0 to 1, where a DI of unity
represents completely polar radial displacement, and
smaller values indicate increasing dyskinetic motion.
In order to measure early infarct zone dyskinetic
motion, DI was calculated on D2 post-MI using a
short-axis slice 2 mm superior to the apex of the LV.
VevoStrain speckle tracking software was used to obtain
endocardial radial displacements for 96 segments over the
course of a cardiac cycle (VisualSonics Inc.) and DI was
calculated as defined by Equation 2.

MRI
MRI was performed in a subset of mice on D2 post-MI
to determine infarct size, and on D28 post-MI to confirm
volumetric results using previously described methods on
a 7T MRI scanner (Bruker, Ettlingen, Germany) (Helm
et al. 2008). Infarct sizes were determined in cMatrixtreated (n = 3) and infarcted control (n = 6) mice on day
2 post-MI using late gadolinium-enhanced (LGE) CMR
images. Infarct size was expressed as a percentage of the
total LV mass. Post-MI day 28 volumetrics were determined for 3 cMatrix-treated mice using a black blood
gradient echo pulse sequence imaging as described
previously (Helm et al. 2008). A set of six to eight contiguous SA cine images were then acquired to cover the
entire LV.

Tissue harvesting and histology
At D29 post-MI, the mice were killed with an overdose of
anesthetic, and death was confirmed by cervical dislocation. Hearts were immediately excised and washed in
PBS. The apical half of each heart was fixed in paraformaldehyde overnight at 4°C. The tissue was then washed
three times in PBS and stored in 70% ethanol prior to
embedding in paraffin and sectioning (5 lm thickness).
Tissue sections were then stained with picrosirius red to
detect collagen.

Statistical analysis
All data are presented as mean  SEM. Statistical significance was presumed where P < 0.05. Data collected during reperfusion (days 2–28) were analyzed using two-way
ANOVA for repeated measures. Post hoc analyses (Bonferroni post tests) were performed where appropriate. All
other statistical analysis was performed using a two-tailed,
unpaired Student’s t-test. Statistical analyses were
performed using Minitab version 16.1.1 (Minitab Inc,
Pennsylvania State University).
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Results
cMatrix composition
Using the Lowry total protein assay, cMatrix had a total
protein concentration of 5.1 mg/mL. Concentration of
collagen types I through V was 240 mg per mg of total
protein. Both the total protein and collagen concentration
of cMatrix are comparable to the levels reported in similar extracts, such as Myogel and Matrigel (Kleinman et al.
1986; Abberton et al. 2008). The composition of cMatrix
is likely most similar to that of the skeletal musclederived Myogel, which contains a mixture of predominately Type I and Type IV collagens, in addition to laminins, proteoglycans, and growth factors.

LV remodeling and cardiac function
The LV remodeling study included 9 control and 6 cMatrix-treated mice subjected to 60 min of ischemia followed by reperfusion. Mortality during surgery and over
the course of the imaging period was similar in control
and cMatrix-treated groups: one mouse from the control
group died on day 3 post-MI after a poor recovery from
surgery, and a cMatrix-treated mouse had to be killed
during the last week of the study due to inadvertent
injury. Volumetric data are reported relative to the baseline LV volumes for each group due to a small, but statistically significant, difference in baseline LV end-diastolic
volume (LVEDV) between groups.
Serial 3D echocardiography performed at baseline and
on days 2, 7, 14, and 28 post-MI showed improved LV
remodeling and cardiac function in cMatrix-treated mice
(Fig. 2). Late-gadolinium-enhanced (LGE) CMR imaging
performed on day 2 confirmed no significant difference
in acute infarct size as a percent of LV mass between
groups (controls = 31.4  1.3% of LV, cMatrixtreated = 35.4  6.8% of LV; P = NS). Relative LV endsystolic volume (LVESV) was found to be significantly
reduced in cMatrix-treated mice by day 14 and remained
significant (P < 0.05) at day 28 (Fig. 2A; results expressed
as fold changes relative to baseline). On day 28, the cMatrix-treated mice showed a 28% improvement in relative
LVESV compared to the control group. While there was
no significant difference in LVEDV between groups
(Fig. 2B), LV ejection fraction (EF) was also found to be
significantly improved in cMatrix versus control mice by
day 14 and remained improved through day 28 (Fig. 2C;
P < 0.05 at both time points). On day 28, EF was
35.0  3.0% in cMatrix-treated mice versus 27.1  2.0%
in controls. By day 28, relative stroke volume (SV) was
22% greater in cMatrix vs. control mice (Fig. 2D;

ª 2015 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Figure 2. cMatrix treatment helps to preserve cardiac function and inhibits post-MI LV remodeling. (A) Relative LVESV was significantly
reduced in the cMatrix-treated group (n = 6), compared to controls (n = 9) by day 14 post-MI. (B) Relative LVEDV was reduced at each time
point measured over 28 days post-MI, although this trend failed to achieve statistical significance. (C) EF in the cMatrix group was significantly
improved over the untreated group at days 14 and 28 post-MI. (D) By day 28, SV was significantly improved in the cMatrix-treated group.
*P < 0.05 vs. untreated, infarcted control group at the same time point.

P < 0.05). A CMR follow-up study was performed to
confirm these results in a subset of animals on day 28
(n = 3). No statistically significant differences in LVESV
or LVEDV were found between the two modalities.

Early infarct zone dyskinetic wall motion
To determine the effect of cMatrix on early infarct dyskinesia, displacement data were obtained from speckle tracking
analysis of echocardiographic image series collected on day
2 post-MI from short-axis (SA) image planes positioned
2 mm superior to the apex of the heart. Figure 3A shows a
short-axis image of an uninfarcted heart in systole, with
arrows representing displacement vectors. A post-MI day 2
animal with severe paradoxical systolic bulging in the anterior and anterolateral segments of myocardium is shown in
Figure 3B, with the area of dyskinetic motion highlighted
in the white box, and in Figure 3C. Figure 3D shows a map
defining the locations of the endocardial radial displacements that were determined over the course of a complete
heart cycle. Figure 3E–G show graphs with the SA linearized along the y-axis, allowing displacement data (z-axis)
over the course of the cardiac cycle (x-axis) to be viewed
for each SA segment in an uninfarcted mouse (Fig. 3E), an
untreated control mouse on day 2 post-MI (Fig. 3F), and a

day 2 post-MI cMatrix mouse (Fig. 3G). Note that
although both MI groups show deficits in contractile function in the anterolateral wall, the cMatrix group is protected from regional bulging (orange box). These findings
were quantified using the novel DI metric, which was found
to be significantly improved in cMatrix-treated (91.2 
2.2%) versus untreated hearts (71  5.2%; Fig. 3H,
P < 0.005).

Histological confirmation of cMatrix
injection and reinforcement of the LV
The presence of cMatrix in the LV was confirmed by observing a thickening of the anterior septum surrounding the site
of injection using CMR imaging on day 28 (Fig. 4A) and by
histological analysis (Fig. 4B). Picrosirius red staining
revealed a significant collagen deposit reinforcing the anteroseptal wall. Figure 4C demonstrates the border (dashed line)
between native collagen tissue deposition (right) and the
relatively denser-staining, and less cellular injected matrix.
The extent of wall thinning, measured by ultrasound as the
percentage of long-axis tissue with a thickness of less than
0.5 mm on ultrasound, was significantly decreased in the
cMatrix-treated group as early as post-MI day 2 (Fig. 4D).
This decrease was preserved on day 28 (P < 0.05).
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Discussion
This study describes the preparation and evaluation of
cMatrix, a novel cardiac muscle-derived biomaterial. After
reperfused MI, cMatrix-treated mice were shown to have
reduced LV remodeling compared to infarcted control
mice. Furthermore, speckle tracking displacement data
were used to show that cMatrix reduced early infarct zone
dyskinesia, as quantified using the novel dyskinesia index
(DI).
The cMatrix extract provides a number of advantages
over previously tested scaffolds. Unlike solid scaffolds or
patches, liquid scaffolds are not limited to superficial
placement on the epicardial surface of the heart and have
the ability to fully adapt to their environment (Singelyn
and Christman 2010).
Furthermore, because they can be implanted via percutaneous trans-coronary-venous or transendocardial injection,
liquid scaffolds have greater clinical potential than patches,
which can only be implanted surgically (Singelyn and

Christman 2010). As cMatrix is an acellular therapy, it
avoids risks of aberrant cellular differentiation and inadvertent cell seeding in off-target organs, as well as the potential
ethical concerns associated with embryonic stem cells.
Because cMatrix is a naturally derived material, all its
components are biocompatible and can be safely degraded
or renewed in vivo. Additionally, synthetic compounds
lack the rich combination of proteins, polysaccharides,
and other ECM components that exist in a direct cardiac
tissue extract such as cMatrix. Finally, cMatrix is directly
derived from cardiac tissue, and therefore provides the
closest possible approximation of the native cardiac environment critical to both safety and efficacy. A humanderived version of cMatrix could be produced with minimal manipulation and might well meet the FDA criteria
for a Human Cell and Tissue Product (HCT/P), thus
finding its way to the bedside more rapidly than many
medical devices or drugs.
A potential limitation of this study is the use of
untreated, infarcted mice as the negative controls, as
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opposed to infarcted mice injected with an equal volume
of vehicle. However, we elected to use untreated, infarcted
animals to better approximate the clinical situation in
which patients either would receive treatment or would
be left untreated. Furthermore, trauma from the needle
and injected fluid might worsen cardiac function in such
a vehicle control group, thus potentially overestimating
the efficacy of cMatrix treatment relative to uninjected
controls. A second potential limitation of this study is
that it did not directly compare the injection of cMatrix
to Matrigel or an alternative mixture of ECM proteins.
While such alternative tissue extracts or ECM mixtures
might well be successful in attenuating LV remodeling
(Dai et al. 2005; Singelyn et al. 2012), one can predict
that the power of such a comparative study would have
to be much greater, involving many more animals, in
order to capture a statistical difference between two or
more materials.
The cardiac matrix preparation is a complex solution
containing ECM and cardiac muscle—in essence a liquefied tissue product. Some elements of the extract promote
cardiac regeneration and others appear to serve as a biocompatible delivery vehicle. Although it is of scientific
importance to identify and understand which key components of the extract support regenerative activity, there is
also value inherent in the simplicity of this biomaterial.
The Food and Drug Administration employs the concept
of minimal manipulation in classifying therapeutic agents
produced from cells and tissues. The cardiac matrix
described here is minimally manipulated and, arguably,
could be available for clinical use as a human or cell
product far sooner than a purified, manufactured product
representing only the “active” ingredients in an approved
carrier/delivery system. In the latter case, as a medical
device or PMA, the FDA would require clinical trials,
adding significantly to the time to bring the potential
therapy to the patient.
Early dyskinesia after MI has previously been shown to
contribute to LV remodeling (French and Kramer 2007).
Indeed, our laboratory has previously demonstrated that
the extent of this early paradoxical wall motion is an
extremely strong predictor of subsequent LV remodeling
(Li et al. 2011). This relationship may be the result of
repeated cycles of systolic bulging and abnormal loading
conditions causing infarct expansion and leading to positive feedback between LV remodeling and cardiac dysfunction in the subacute period prior to the formation of
mature scar (Mann and Bristow 2005; French and Kramer
2007). In this study, we demonstrate that injection of
cMatrix reduced early infarct zone dyskinesia independent
of infarct size and attenuated LV remodeling, compared
to infarcted controls. This effect could be seen as early as
post-MI day 2, prior to the development of significant
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differences in systolic function and chamber sizes. This
time point is prior to the onset of significant infarct
expansion, scar formation, and other regenerative processes, such as neovascularization. It is therefore likely
that cMatrix reduced LV remodeling at least partially
through this direct mechanical mechanism.
The importance of early reinforcement could be further tested by assessing LV remodeling after delivering
cMatrix at later time points post-MI. If early reinforcement is critical to the inhibition of LV remodeling, it is
conceivable that targeting genes that control early ECM
degradation (e.g., MMPs or TIMPs) may also have therapeutic effects on LV remodeling. This strategy would
become particularly attractive with the advent of new
gene delivery systems that rapidly and selectively target
the infarct border zone after reperfused MI (Konkalmatt
et al. 2012).
The nonstructural effects of cMatrix on LV remodeling
remain to be examined, but are likely to be highly complex, in part because ECM composition over the course
of LV remodeling is a dynamic and delicate balance of
degradation and synthesis (French and Kramer 2007;
Akhyari et al. 2008). In addition, various components of
the ECM may have different effects on LV remodeling
depending on their relative abundance and surrounding
environment. For example, fibronectin fragments stimulate ECM degradation, but have also been shown to
prevent apoptosis in injured cardiomyocytes (Arslan et al.
2011). Furthermore, extracts rich in basement membrane,
such as cMatrix, have been shown to promote angiogenesis (Kleinman and Martin 2005). While the primary focus
of this study was on the early mechanical effects of the
cMatrix injection, a more detailed analysis of the effect of
cMatrix on endogenous ECM synthesis and degradation
post-MI could potentially shed light on additional mechanisms behind the treatment’s effects on remodeling.
Much of the complex role of ECM in LV remodeling
remains to be defined. Analysis and selective modification
of cMatrix content may yield insight into the factors and
mechanisms contributing to cardiac regeneration, paving
the way for other novel strategies for curtailing LV
remodeling post-MI.
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